Cancer Communications
indexed by SCI

doi: 10.5732/cjc.011.10326
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology
Xue Xue, Xing-Jie Liang
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology of China, Beijing 100190, P. R. China.
[Abstract] Multidrug resistance (MDR), which significantly decreases the efficacy of anticancer drugs and causes tumor recurrence, has been a major challenge in clinical cancer treatment with chemotherapeutic drugs for decades. Several mechanisms of overcoming drug resistance have been postulated. Well known P-glycoprotein (P-gp) and other drug efflux transporters are considered to be critical in pumping anticancer drugs out of cells and causing chemotherapy failure. Innovative theranostic (therapeutic and diagnostic) strategies with nanoparticles are rapidly evolving and are anticipated to offer opportunities to overcome these limits. In this review, we discuss the mechanisms of drug efflux-mediated resistance and the application of multiple nanoparticle-based platforms to overcome chemoresistance and improve therapeutic outcome.
Chinese Journal of Cancer 2012, Volume: 31, Issue 2, Page: 100-109
[ PDF Full-text ]
[ Html full-text ](PubMed Central)

[ PubMed ]

[Google Scholar]

Cite this article

Xue Xue, Xing-Jie Liang. Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer. 2012, 31(2):100-109. doi:10.5732/cjc.011.10326

Export citations



Your Comments




CC Wechat 微信公众号


Editorial Manager

CC adopts Editorial Manager to manage its submissions from Dec.18, 2014


Reference style for  

 Reference Manager

Editorial Manager





Advanced search


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China